Cookies on the JDRF website

Our website uses cookies to make your experience as great as possible. By continuing to use the website, we will assume that you agree to the use of cookies on the website. However, if you would like to change your cookie settings, please visit the website of The Information Commissioner's Office to find out how to control or delete cookies on your browser.

All news

Find out the latest news about JDRF's research and fundraising events.

Displaying January 2010


Big partnership – small needles!

JDRF has joined forces and medical technology company BD (Becton, Dickinson and Company) to launch an innovative programme to make insulin pumps more effective and more user-friendly.

Key to this partnership will be working with BD’s ‘microneedle’ technology. Microneedles are tiny needles that could deliver insulin to just beneath the skin, which would not only increase the speed at which insulin is delivered to the body, but may also be virtually pain free.

Through the programme, JDRF will support BD's research and development of new products that deliver insulin from a pump to a patient – this might be either as a standard infusion set connected to a ‘standard’ insulin pump or as a ‘patch pump’ where the actual pump would sit on the skin as well, without any connective tubing.

By developing a new pump that could minimizing pain, kinking and site infections we could expect to see improvements in how people with type 1 diabetes are able to control their insulin therapy. This would in turn have a positive impact on their overall level of glycaemic control.

‘Having better control over your glucose levels means better health outcomes for people with diabetes,’ said Rachel Connor, Research Relations Manager at JDRF. ‘And if we can make insulin pumps easier to use and more wearable, we hope more people will want to use these technologies."

The JDRF will invest $4.3 million in the partnership over the next few years. Ultimately JDRF hopes that the new pump developed through the partnership could form a critical element of a closed-loop artificial pancreas system.


Artificial Pancreas: a new leap forward

Today Juvenile Diabetes Research Foundation International announced an innovative partnership with Animas Corporation to begin work on bringing an automated ‘artificial pancreas’ closer to reality for people living with type 1 diabetes.

Animas, a Johnson & Johnson company, is a leading manufacturer and distributor of insulin delivery and glucose management systems. JDRF is a global leader in research leading to better treatments and cures for type 1 diabetes.

This major industry initiative within the JDRF Artificial Pancreas Project has an ambitious set of objectives. Not only will the partnership aim to develop a ‘first generation’ partially automated system to manage type 1 diabetes and conduct extensive clinical trials for safety and efficacy, but it will also aim to submit the system for regulatory approval in the next four years.

The idea behind the Artificial Pancreas Project is to link two existing technologies, insulin pumps and continuous glucose sensors. This first generation system aims to increase the time people with type 1 spend in the ‘target’ range – avoiding hypoglycaemia (low blood glucose levels) and serious hyperglycaemia (high blood glucose levels).

This programme is focused on limiting hyperglycaemia. Systems exist to limit hypoglycaemia by shutting off insulin delivery, but to limit hyperglycaemia extra insulin must be administered – but not deliver so much that it causes glucose levels to drop too low and induce hypoglycaemia.

‘This partnership will begin the process of automating how people with type 1 diabetes manage their blood glucose’ said Karen Addington, Chief Executive of JDRF in the UK. ‘The ultimate goal is to have a fully automated system which can control blood glucose without input from the person using the system. But this “hypoglycaemia-hyperglycaemia minimiser” system could bring dramatic changes in the quality of life for people with type 1 diabetes, beginning to free them from the constant balancing act of testing, calculating doses and treating themselves throughout the day. It would represent a significant step forward, providing immediate benefits in terms of blood glucose control, and reducing the risk of developing long term complications of living with type 1’

‘Animas is committed to helping people with diabetes live their lives without limits,’ Henry Anhalt, DO, Medical Director, Animas Corporation said ‘We are proud to be working with JDRF on this critical programme.’

JDRF will provide $8 million in funding over the next four years for this project.

To support JDRF in delivering the Artifiical Pancreas and finding the cure for type 1 please donate now.